Please login to the form below

Not currently logged in
Email:
Password:

Amgen's Q3 hit by $780m settlement charge

Amgen recorded a net profit drop of 63 per cent due mainly to a settlement charge of $780m related to allegations of improper sales and marketing practices

Amgen recorded a net profit drop of 63 per cent due mainly to a settlement charge of $780m related to allegations of improper sales and marketing practices.

The US-based biopharmaceutical company said the money had been set aside to cover ongoing settlement discussions that included state Medicaid investigations and 10 whistle-blower lawsuits.

Among these lawsuits was Westmoreland v Amgen, a suit filed by former sales representative Kassie Westmoreland involving the company's marketing practices for anaemia treatment Aranesp (darbepoetin alfa).

The company stated: 'The proposed settlement remains subject to continuing discussions regarding the components of the agreement and the completion and execution of all required documentation.'

Excluding the settlement charge, the company's results were more positive, with revenue up 3 per cent to $3.95bn for the third quarter of 2011.

Adjusted earnings per share (EPS) increased by 3 per cent too, climbing to $1.40 for the quarter.

Most products saw healthy growth, although sales of both Aranesp and Epogen (epoetin alfa) were down following new safety warnings issued by the US Food and Drug Administration (FDA) in June 2011.

25th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics